耐甲氧西林金黄色葡萄球菌（MRSA）感染治疗的未来趋势：一种对持久病原体有效的新型抗生素的深入综述。
Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.
机构信息
Department of Microbiology, University Hospital Crosshouse, Kilmarnock KA2 0BE, UK.
Departments of Medicine, Paediatrics, and Public Health Sciences, University of Chicago, Chicago, IL 60637, USA.
出版信息
J Glob Antimicrob Resist. 2017 Sep;10:295-303. doi: 10.1016/j.jgar.2017.05.019. Epub 2017 Jul 18.
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health problem. Vancomycin and teicoplanin have been in clinical use for several decades but their drawbacks are well described. In the last 10 years, several antibiotics have been made available for clinical use. Daptomycin and linezolid have been extensively used during this period. Other agents such as ceftaroline, ceftobiprole, dalbavancin, oritavancin, tedizolid and telavancin have been approved by regulatory agencies since 2009. Many others, such as the newer tetracyclines, fluoroquinolones, oxazolidinones and pleuromutilins, are in various stages of development. In addition, an ongoing multicentre trial is investigating the role of combination of vancomycin or daptomycin with β-lactam antibiotics. This review discusses the role of the newer antibiotics, reflecting the views of the 6th MRSA Consensus Conference meeting of the International Society of Chemotherapy MRSA Working Group that took place in 2016.
耐甲氧西林金黄色葡萄球菌（MRSA）仍然是一个主要的公共卫生问题。万古霉素和替考拉宁已在临床上使用了几十年，但它们的缺点已得到充分描述。在过去的 10 年中，已经有几种抗生素可用于临床。达托霉素和利奈唑胺在此期间得到了广泛应用。自 2009 年以来，其他一些药物，如头孢洛林、头孢比普、达巴万星、奥利万星、替加环素和替考拉宁，已获得监管机构的批准。还有许多其他药物，如新型四环素类、氟喹诺酮类、恶唑烷酮类和截短侧耳素类，处于不同的开发阶段。此外，一项正在进行的多中心试验正在研究万古霉素或达托霉素与β-内酰胺类抗生素联合使用的作用。这篇综述讨论了新型抗生素的作用，反映了 2016 年举行的国际化疗协会 MRSA 工作组第 6 次耐甲氧西林金黄色葡萄球菌共识会议的观点。
Zotero 插件